| Autor: |
Abusara OH; Faculty of Pharmacy, Al-Zaytoonah University of Jordan, Amman 11733, Jordan., Ibrahim AIM; Faculty of Pharmacy, Al-Zaytoonah University of Jordan, Amman 11733, Jordan., Issa H; Aurum Biotech, Amman 11941, Jordan., Hammad AM; Faculty of Pharmacy, Al-Zaytoonah University of Jordan, Amman 11733, Jordan., Ismail WH; Faculty of Pharmacy, Al-Zaytoonah University of Jordan, Amman 11733, Jordan. |
| Jazyk: |
angličtina |
| Zdroj: |
Current issues in molecular biology [Curr Issues Mol Biol] 2023 Mar 06; Vol. 45 (3), pp. 2170-2181. Date of Electronic Publication: 2023 Mar 06. |
| DOI: |
10.3390/cimb45030139 |
| Abstrakt: |
Aldehyde dehydrogenase (ALDH) enzymes are involved in the growth and development of several tissues, including cancer cells. It has been reported that targeting the ALDH family, including the ALDH1A subfamily, enhances cancer treatment outcomes. Therefore, we aimed to investigate the cytotoxicity of ALDH1A3-affinic compounds that have been recently discovered by our group, on breast (MCF7 and MDA-MB-231) and prostate (PC-3) cancer cell lines. These compounds were investigated on the selected cell lines as single treatments and in combination with doxorubicin (DOX). Results showed that the combination treatment experiments of the selective ALDH1A3 inhibitors (compounds 15 and 16 ) at variable concentrations with DOX resulted in significant increases in the cytotoxic effect on the MCF7 cell line for compound 15 , and to a lesser extent for compound 16 on the PC-3 cell line, compared to DOX alone. The activity of compounds 15 and 16 as single treatments on all cell lines was found to be non-cytotoxic. Therefore, our findings showed that the investigated compounds have a promising potential to target cancer cells, possibly via an ALDH-related pathway, and sensitize them to DOX treatment. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
